Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Trigonelline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.62 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trigonelline SCHEMBL679317 | 0.98 | NNMT (0.68) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL29581532 | 0.98 | NNMT (0.68) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL5013564 | 0.96 | NNMT (0.66) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL15361649 | 0.96 | NNMT (0.66) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL26615275 | 0.92 | NNMT (0.61) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL11786615 | 0.84 | USP2 (0.57) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Hydrochloric Acid SCHEMBL2293932 | 0.83 | NNMT (0.66) | NNMTUSP2APOBEC3AAPOBEC3GTSHR | |
| Trigonelline SCHEMBL8016829 | 0.82 | USP2 (0.58) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL10256967 | 0.82 | NNMT (0.63) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonellamide SCHEMBL5145685 | 0.82 | NNMT (0.96) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111593378-A | Preparation of high corrosion-resistant alkaline zinc-nickel alloy electroplating solution and components of additive | 常州新纪元材料科技有限公司 | 2020-08-28 | — | — | CN | claimed |
| WO-2007053773-A1 | COMPOSITIONS AND METHODS USING NICOTINIC ACID FOR TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE | HENDRIX CURT (US) | 2007-05-10 | — | — | WO | claimed |
| US-20070105793-A1 | Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease | CONCOURSE HEALTH SCIENCES LLC | 2007-05-10 | — | — | US | claimed |
| US-3972787-A | Palladium electrolyte baths utilizing quaternized pyridine compounds as brighteners | LEA-RONAL, INC. (US) | 1976-08-03 | — | — | US | claimed |
| CN-118436648-A | Application of trigonelline hydrochloride in preparation of medicine for preventing or treating gout | 福建中医药大学 | 2024-08-06 | — | — | CN | disclosed |
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. | 2023-07-20 | — | — | US | disclosed |
| EP-3512486-B2 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2023-07-12 | — | — | EP | disclosed |
| US-20220241259-A1 | COMPOSITIONS AND METHODS USING TRIGONELLINE AND VITAMINS FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLE | NESTLE SA (CH) | 2022-08-04 | — | — | US | disclosed |
| EP-3512486-B1 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2020-10-21 | — | — | EP | disclosed |
| CN-111593378-A | Preparation of high corrosion-resistant alkaline zinc-nickel alloy electroplating solution and components of additive | 常州新纪元材料科技有限公司 | 2020-08-28 | — | — | CN | disclosed |
| WO-2007053773-A1 | COMPOSITIONS AND METHODS USING NICOTINIC ACID FOR TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE | HENDRIX CURT (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105793-A1 | Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease | CONCOURSE HEALTH SCIENCES LLC | 2007-05-10 | — | — | US | disclosed |
| US-3972787-A | Palladium electrolyte baths utilizing quaternized pyridine compounds as brighteners | LEA-RONAL, INC. (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | AIFM2, GPX4, SLC40A1 | ACHE 4874/4885NNMT 1055/4885USP2 1001/4885 |
| US-20220241259-A1 | COMPOSITIONS AND METHODS USING TRIGONELLINE AND VITAMINS FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLE | NQO1, SIRT3, NADK | ACHE 226/4885NNMT 56/4885USP2 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.